AMRN


Amarin (AMRN): Management Is Flying in the Dark

A lot of Amarin (AMRN) stock bulls expected shares to fly up toward $30 following shockingly good results of the company’s Reduce-It cardiovascular …

Amarin (AMRN) Stock: This Bull Isn’t Bullish Enough

Amarin (AMRN) has been Wall Street’s biggest standout of 2018, with shares skyrocketing nearly 240%. The biggest question for investors, then, is whether …

Here’s Why Amarin (AMRN) Stock Soared Today

Shares of Amarin (AMRN), an Irish biopharma that markets a prescription fish oil medication called Vascepa, are on the move following the company’s …

Why Amarin (AMRN) Stock May Be a Good Buy Right Now

Amarin (AMRN) has had a lot of attention over its fish oil pill Vascepa, which aims to help those with cardiovascular problems and …

Billionaire Izzy Englander Throws Chunk of Amarin (AMRN) Stock Out to Sea, But Reels in Bausch Health (BHC)

70-year-old Israel “Izzy” Englander, worth $6 billion to date, was born the same year as the state of Israel, and just one year …

Amarin (AMRN) Stock Will Rise Again When the Dust Settles, Says Analyst

In early November, fish oil drug maker Amarin (AMRN) presented data called REDUCE-IT at the American Heart Association scientific sessions for a medication …

Investing Guru Andrew Spokes Chops Position in Amarin (AMRN) Stock, Picks Up Tilray (TLRY)

Andrew Spokes, managing partner at Farallon Capital Management stepped in for founder Thomas Steyer in 2013 and has been hedging big bets for …

Analyst Defends Amarin (AMRN) Stock as EU Regulators Say Omega 3 is Ineffective

Amarin (AMRN) stock tumbled nearly 5% yesterday after European regulators deemed all Omega-3 fatty acid pills/medicines in Europe ineffective in preventing cardiovascular events. …

What New Information is Causing This Bull to Charge Ahead for Amarin (AMRN) Stock?

The Amarin (AMRN) saga is not over yet. Following a somewhat dramatic couple of weeks after the release of the biopharmaceutical’s drug, Vascepa, analysts …

Does Amarin’s (AMRN) Impending FDA Decision Matter?

Blogger Christiana Friedman says the FDA decision for Amarin’s (AMRN) drug Vascepa might not be the make or break for the company. In …